Literature DB >> 8891199

Cytokines and pulmonary fibrosis.

K Zhang1, S H Phan.   

Abstract

In the past several years, significant progress in many aspects of pulmonary fibrosis research has been made. Among them, the finding that a variety of cytokines play important roles in the complex process appears most intriguing. These cytokines include at least transforming growth factor-beta (TGF-beta), tumor necrosis factor-alpha (TNF-alpha), platelet-derived growth factor, fibroblast growth factors, (TGF-alpha), interleukin-1, monocyte chemoattractant protein-1 and macrophage inflammatory protein-1 alpha. These cytokines have been demonstrated to be produced at the sites of active fibrosis where they appear to be expressed by activated inflammatory cells, such as macrophages and eosinophils. More interestingly, other noninflammatory lung cells including mesenchymal cells, such as myofibroblasts, and epithelial cells, have been found to be significant sources as well, albeit in most instances at somewhat different time points than those by inflammatory cells. Study of the individual cytokines in vitro has revealed a variety of potential roles for these cytokines in the regulation of the fibrotic process in vivo, including chemoattractant, mitogenic activities for fibroblasts, stimulation of extracellular matrix and alpha-smooth muscle actin gene expression, alteration of the contractile phenotype of fibroblasts and regulation of diverse functions of lung inflammatory and epithelial cells which can further impact on the fibrotic process by autocrine and paracrine mechanisms. Of these cytokines, it appears that TGF-beta is probably the most important cytokine in terms of the direct stimulation of lung matrix expression which typifies fibrosis. Recently however, there is accumulating evidence to indicate that the situation is much more complex than any one single cytokine being solely responsible for the fibrotic response. The concept of complex lung cytokine networks, orchestrated by a few key cytokines, such as TNF-alpha, being responsible for this response has received strong support from recent studies. This means that it is the balance of positive (profibrogenic) and negative (antifibrogenic) forces generated from interaction among the various cytokines constituting these networks, which may finally determine the outcome of lung injury and inflammation. The importance of these cytokines also suggests new potential targets for designing new therapies for progressive pulmonary fibrosis, and perhaps their utility in prognostication as well.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8891199     DOI: 10.1159/000109195

Source DB:  PubMed          Journal:  Biol Signals        ISSN: 1016-0922


  30 in total

1.  Protective role of NKT cells and macrophage M2-driven phenotype in bleomycin-induced pulmonary fibrosis.

Authors:  Felipe Grabarz; Cristhiane Favero Aguiar; Matheus Correa-Costa; Tárcio Teodoro Braga; Meire I Hyane; Vinícius Andrade-Oliveira; Maristella Almeida Landgraf; Niels Olsen Saraiva Câmara
Journal:  Inflammopharmacology       Date:  2017-08-04       Impact factor: 4.473

2.  Osteopontin modulates inflammation, mucin production, and gene expression signatures after inhalation of asbestos in a murine model of fibrosis.

Authors:  Tara Sabo-Attwood; Maria E Ramos-Nino; Maria Eugenia-Ariza; Maximilian B Macpherson; Kelly J Butnor; Pamela C Vacek; Sean P McGee; Jessica C Clark; Chad Steele; Brooke T Mossman
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

3.  Antifibrotic role of HGF in sarcoidosis.

Authors:  Martin Faehling; Martin Hetzel; Diana Anders; Gerlinde Trischler; Max Bachem
Journal:  Lung       Date:  2012-02-05       Impact factor: 2.584

4.  Titration of non-replicating adenovirus as a vector for transducing active TGF-beta1 gene expression causing inflammation and fibrogenesis in the lungs of C57BL/6 mice.

Authors:  G Sakuntala Warshamana; Derek A Pociask; Krishna J Fisher; Jing-Yao Liu; Patricia J Sime; Arnold R Brody
Journal:  Int J Exp Pathol       Date:  2002-08       Impact factor: 1.925

5.  Fibroblast growth factor 2 is required for epithelial recovery, but not for pulmonary fibrosis, in response to bleomycin.

Authors:  Robert D Guzy; Ivan Stoilov; Timothy J Elton; Robert P Mecham; David M Ornitz
Journal:  Am J Respir Cell Mol Biol       Date:  2015-01       Impact factor: 6.914

6.  Crosstalk Between T Lymphocytes and Lung Fibroblasts: Generation of a Hyaluronan-Enriched Extracellular Matrix Adhesive for Monocytes.

Authors:  Léa Gaucherand; Ben A Falk; Stephen P Evanko; Gail Workman; Christina K Chan; Thomas N Wight
Journal:  J Cell Biochem       Date:  2017-04-18       Impact factor: 4.429

Review 7.  Different effects of growth factors on proliferation and matrix production of normal and fibrotic human lung fibroblasts.

Authors:  M Hetzel; M Bachem; D Anders; G Trischler; M Faehling
Journal:  Lung       Date:  2005 Jul-Aug       Impact factor: 2.584

8.  Granuloma formation induced by low-dose chronic silica inhalation is associated with an anti-apoptotic response in Lewis rats.

Authors:  Raymond J Langley; Neerad C Mishra; Juan Carlos Peña-Philippides; Julie A Hutt; Mohan L Sopori
Journal:  J Toxicol Environ Health A       Date:  2010

Review 9.  Antioxidants as potential therapeutics for lung fibrosis.

Authors:  Brian J Day
Journal:  Antioxid Redox Signal       Date:  2008-02       Impact factor: 8.401

Review 10.  Pharmacotherapy of acute lung injury and acute respiratory distress syndrome.

Authors:  Krishnan Raghavendran; Gloria S Pryhuber; Patricia R Chess; Bruce A Davidson; Paul R Knight; Robert H Notter
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.